← Leaderboards
David M. Nanus
Weill Medical College Of Cornell Univ
$4,374,762
Attributed
$4,374,762
Total exposure
8
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $736.3K · FY2005–07$1M$750K$500K$250K$0
'05
'06
'07
Funding mix
By agency
NIH$4,374,762 · 8
By mechanism
R01$3,685,586 · 2
K24$623,522 · 1
M01$65,654 · 5
Top collaborators
No co-investigators on record.
Most similar at Weill Medical College Of Cornell Univ
Same institution · by research overlap
- John P. Leonard$596,754
- Julianne L Imperato-McGinley$179,286,606
- Andrew H Talal$562,525
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectProstate NeoplasmsClinical ResearchClinical Trial Phase IHuman Therapy EvaluationLaboratory MouseRetinoateNeoplasm /Cancer ChemotherapyMonoclonal AntibodyNeoplasm /Cancer ImmunotherapyLiposomesNutrition Related TagMaleNeoplasm /Cancer GeneticsMetastasisCombination Cancer TherapyDrug Screening /EvaluationTissue /Cell CultureProstate Specific AntigenNeoplastic ProcessPatient Oriented ResearchCell Growth RegulationCarcinogenesisAntitumor Antibody
Grant awards (21)
PHASE II TRIAL OF 177LU-J591 IN METASTATIC, ANDROGEN-INDEPENDENT PROSTATE CANCER$3,510
M01 · FY2007 · RR · contact PI
PHASE I TRIAL OF ATRA-IV & DEPAKOTE IN PTS W/ADVANCED SOLID TUMOR MALIGNANCIES$8,914
M01 · FY2006 · RR · contact PI
Modulation of retinoic acid action in renal cancer$381,213
R01 · FY2005 · CA
Neutral Endopeptidase inactivation in advanced prostate$318,660
R01 · FY2005 · CA
PHASE I TRIAL OF ATRA-IV &DEPAKOTE IN PTS W/ADVANCED SOLID TUMOR MALIGNANCIES$36,440
M01 · FY2005 · RR
Modulation of retinoic acid action in renal cancer$351,713
R01 · FY2004 · CA
Neutral Endopeptidase inactivation in advanced prostate$318,660
R01 · FY2004 · CA
ANTI TUMOR THERAPIES FOR GENIOTURINARY MALIGNANCIES$130,580
K24 · FY2004 · CA
Phase I 111-Indium radiolabeled mAb huJ591/ metastatic solid tumors$15,988
M01 · FY2004 · RR
Chemoprevention of Prostate Cancer with Finasteride$802
M01 · FY2004 · RR
Modulation of retinoic acid action in renal cancer$351,713
R01 · FY2003 · CA
Neutral Endopeptidase inactivation in advanced prostate$318,660
R01 · FY2003 · CA
ANTI TUMOR THERAPIES FOR GENIOTURINARY MALIGNANCIES$127,562
K24 · FY2003 · CA
Modulation of retinoic acid action in renal cancer$351,713
R01 · FY2002 · CA
Neutral Endopeptidase inactivation in advanced prostate$318,660
R01 · FY2002 · CA
ANTI TUMOR THERAPIES FOR GENIOTURINARY MALIGNANCIES$124,634
K24 · FY2002 · CA
Modulation of retinoic acid action in renal cancer$351,713
R01 · FY2001 · CA
NEUTRAL ENDOPEPTIDASE INACTIVATION IN ADVANCED PROSTATE$316,044
R01 · FY2001 · CA
ANTI TUMOR THERAPIES FOR GENIOTURINARY MALIGNANCIES$121,790
K24 · FY2001 · CA
NEUTRAL ENDOPEPTIDASE INACTIVATION IN ADVANCED PROSTATE$306,837
R01 · FY2000 · CA
ANTI TUMOR THERAPIES FOR GENIOTURINARY MALIGNANCIES$118,956
K24 · FY2000 · CA